Controlling Inflammation Due to Cardiac Devices

描述(由申请人提供)：NovelMed的主要候选药物可防止生物材料诱导的细胞激活。在需要心脏设备的外科手术中，激活的细胞释放炎症介质，这些介质负责导致病理创伤，导致心脏、肺、肝脏和脑损伤。我们的发现为开发YalcixiMab作为一种治疗方法提供了令人信服的支持，以防止手术过程中发生的生物材料诱导的炎症。CPB电路用于心脏移植和瓣膜置换的各种程序。在体外循环前用YalcioMab治疗血液可以防止补体激活、中性粒细胞激活、单核细胞激活、血小板激活和白细胞-血小板聚集体的形成。该药物还可以防止释放强有力的炎症介质，如肿瘤坏死因子-1。。 公共卫生相关性：NovelMed正在开发治疗方法，以减少/预防血液暴露在心脏装置的生物材料表面时出现的并发症。在几个心脏手术中，体外循环电路被用作心肺机，而外科医生则在空心脏上进行手术。这项提议的最终目标是开发技术，以改进人造人体组织的制造。

DESCRIPTION (provided by applicant): NovelMed's lead drug candidate prevents biomaterials induced cellular activation. Activated cells release inflammatory mediators that are responsible for pathological trauma that leads to cardiac, lung, liver, and brain injuries during surgical procedures that require cardiac devices. Our findings provide convincing support for developing YalcixiMab as a treatment to prevent biomaterial-induced inflammation that occurs during surgical procedures. CPB circuits are used during various procedures for heart transplant, and valve replacements. Treatment of blood with YalcioMab prior to the extracorporeal circulation prevents complement activation, neutrophil activation, monocyte activation, platelet activation and the formation of leukocyte-platelet aggregates. The drug also prevents the release of potent inflammatory mediators such as TNF-1. . PUBLIC HEALTH RELEVANCE: NovelMed is developing treatments that will reduce/prevent complications that arise when blood is exposed to biomaterial surfaces of the cardiac devices. Cardiopulmonary bypass circuits are utilized in several cardiac surgeries as a heart-lung machine while surgeons perform procedures on the empty heart. The ultimate objective of this proposal is the development of technologies that will improve the manufacturing of engineered human tissues